FDA approves dual GIP and GLP-1 receptor agonist for chronic weight management

The FDA approved tirzepatide for chronic weight management in adults with obesity or overweight with weight-related medical problems.

The FDA approved tirzepatide for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with weight-related medical problems, such as hypertension, dyslipidemia, T2DM, obstructive sleep apnea or CVD.

This decision was based on the results from the SURMOUNT-1 and SURMOUNT-2 trials.

The tirzepatide injection activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. It should be used as an adjunct to a reduced-calorie diet and increased physical activity.

Source: News Release Lilly, November 9, 2023